Todd Brady
Fortune : 3 M $ au 31/05/2026
Fortune : 3 M $ au 31/05/2026
Todd C.
Brady is the founder of Phenome Sciences, Inc. Current jobs include President, Chief Executive Officer & Director at Aldeyra Therapeutics, Inc. since 2012; President, CEO, Secretary & Director at Helio Vision, Inc.; Director at NovaDigm Therapeutics, Inc. since 2007; and Member at Southeast BIO.
Former jobs include Medical Director & Head-Business Development at ADERIS Pharmaceuticals, Inc.; Director at Cantex Pharmaceuticals, Inc., Sebacia, Inc., Asmacure Ltée, CardioPolymers, Inc., and F-Star Therapeutics, Inc. (United States);.
Independent Director at Outlook Therapeutics, Inc. from 2014 to 2017; Independent Director at Evoke Pharma, Inc. from 2007 to 2025; Independent Director at F-star Therapeutics, Inc. from 2020 to 2023; Principal at Domain Associates LLC; Executive VP-Strategic Development & Planning at Antisoma, Inc.; and Senior Associate at CB Health Ventures.
Education includes an undergraduate degree from Dartmouth College in 1993, a doctorate from Duke University School of Medicine in 1999, and a doctorate from Duke University Graduate School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/06/2026 | 1 721 298 ( 2,85% ) | 3 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Directeur Général | 01/01/2012 |
Southeast BIO | Corporate Officer/Principal | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines to prevent fungal and bacterial infections | Directeur/Membre du Conseil | 01/12/2007 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Directeur Général | - |
| Sociétés | Poste | Fin |
|---|---|---|
| EVOKE PHARMA, INC. | Directeur/Membre du Conseil | 17/12/2025 |
| F-STAR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 08/03/2023 |
| OUTLOOK THERAPEUTICS, INC. | Directeur/Membre du Conseil | 31/10/2017 |
Phenome Sciences, Inc. | Directeur Général | - |
ADERIS Pharmaceuticals, Inc.
ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs and pharmaceuticals | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 20 |
|---|---|
ADERIS Pharmaceuticals, Inc.
ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs and pharmaceuticals | Health Technology |
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for eye diseases | Health Technology |
Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops heparin to ameliorate cardiac ischemia-reperfusion injuries | Health Technology |
Evoke Pharma, Inc.
Evoke Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets drugs to treat gastrointestinal | Health Technology |
Sebacia, Inc.
Sebacia, Inc. BiotechnologyHealth Technology Develops novel technology to treat acne | Health Technology |
Domain Associates LLC
Domain Associates LLC Investment ManagersFinance Domain Associates invests in both private and public companies located in the United States. The firm focuses on pharmaceuticals, diagnostics and medical device sectors. It provides financing for seed, early and late stage capital requirements. It takes a seat on the board of directors. | Finance |
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Antisoma, Inc.
Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and pharmaceuticals | Health Technology |
CB Health Ventures
CB Health Ventures Investment ManagersFinance CB Health Ventures focuses on investment opportunities in healthcare services, medical information technology, biotechnology and genomics | Finance |
Asmacure Ltée
Asmacure Ltée Pharmaceuticals: MajorHealth Technology Develops novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases | Health Technology |
CardioPolymers, Inc.
CardioPolymers, Inc. Pharmaceuticals: MajorHealth Technology Provides novel biocompatible polymer implant therapies to treat cronic heart failures | Health Technology |
Southeast BIO | |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines to prevent fungal and bacterial infections | Health Technology |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology Engages in discovery, development and preparation of bioavailable therapeutics | Health Technology |
Phenome Sciences, Inc. | |
Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
Duke University School of Medicine
Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University Graduate School
Duke University Graduate School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Health Technology |
F-star Therapeutics, Inc.
F-star Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops antibody therapeutics for cancer and other diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national